RAD-140

In vitro bioassays confirm androgenic activity of RAD-140 in reporter gene assays and yeast androgen screens, supporting its mechanism as an androgen receptor agonist. However, no controlled human clinical trials have been published establishing efficacy or safety. Multiple case reports document severe hepatotoxicity including cholestatic drug-induced liver injury, with cases requiring corticosteroids, plasmapheresis, or intensive care admission. Cardiac adverse events including myopericarditis and heart failure have also been reported. RAD-140 is not FDA-approved for clinical use and is prohibited by WADA, yet remains readily available on the consumer market. Long-term safety data are entirely absent.